TBG Diagnostics Limited announced consolidated earnings results for the half year ended June 30, 2018. For the half year, the company reported revenue from continuing operations of AUD 1,670,395 compared to AUD 1,762,020 a year ago. The decline in sales revenues were mainly attributed to sales rebate incentives granted to a major sales distributor for having met the agreed sales targets. This was inspite of new customers obtained during the period. Loss before income tax expense was AUD 2,514,135 compared to AUD 1,571,073 a year ago. Loss from continuing operations was AUD 2,514,135 or 1.11 cents per basic and diluted share compared to AUD 1,571,073 or 0.46 cents per basic and diluted share a year ago. Net loss attributable to equity holders of the company was AUD 2,212,865 or 1.02 cents per basic and diluted share compared to AUD 995,954 or 0.46 cents per basic and diluted share a year ago. Net cash flows used in operating activities were AUD 2,827,687 compared to AUD 798,328 a year ago. Payments for plant and equipment were AUD 1,037,484 compared to AUD 115,310 a year ago. The loss for the six months ended 30 June 2018 was AUD 2,303,646 compared to a loss of AUD 995,954 for the six months ended 30 June 2017. The variance is primarily due to the research and development tax incentive rebate received in 2017 pertaining to 2016 financial year.